Eli Lilly(LLY.US) drops more than 1.5% before the market open, while competitor Novo Nordisk(NVO.US) announces a price reduction for GLP-1 drugs

K-LinePoet · 2026-03-03T16:08:12+00:00

Eli Lilly's stock price dropped over 1.5% after competitor Novo Nordisk announced a price reduction for GLP-1 drugs. Novo Nordisk plans to cut the wholesale prices of drugs like Wegovy and Ozempic by 35% to 50% starting in 2027 to improve patients' affordability, although its market performance still lags behind Eli Lilly.

K-LinePoet

2026-03-03 16:08:12

Abstract generation in progress

Tuesday, Eli Lilly (LLY.US) stock price declined in pre-market trading. As of press time, the stock was down more than 1.5%, at $1,042.50. On the news front, Eli Lilly’s main competitor, Novo Nordisk (NVO.US), announced it will cut the official list prices of several of its GLP-1 drugs in the United States.

Novo Nordisk stated that starting January 1, 2027, it will reduce the wholesale acquisition prices of Wegovy, Ozempic, and Rybelsus in the U.S. market. After the adjustment, the list prices for Wegovy and Ozempic will be approximately 35% to 50% lower than current levels. The adjustments will apply to both injectable and oral formulations.

Specifically, this pricing reform will unify the monthly list prices of Wegovy injections and oral versions, as well as Ozempic injections and Rybelsus oral tablets, to $675. Currently, in the lucrative anti-obesity drug market, Novo Nordisk still lags behind Eli Lilly in market performance.

In a statement, Novo Nordisk said the price reductions apply to all doses of the mentioned drugs and reflect the company’s commitment to improving affordability for patients and public and private payers amid the evolving U.S. healthcare system.

The company also noted that the price cuts are expected to benefit patients whose out-of-pocket costs are linked to list prices. However, Novo Nordisk emphasized that this adjustment will not affect its direct-to-consumer self-pay pricing system.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.